NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03107988 |
|
Recruitment Status :
Active, not recruiting
First Posted : April 11, 2017
Last Update Posted : February 9, 2024
|
Sponsor:
New Approaches to Neuroblastoma Therapy Consortium
Collaborators:
Pfizer
University of Southern California
Solving Kids' Cancer US/EU
Children's Neuroblastoma Cancer Foundation
The Band of Parents
The Evan Foundation
Wade's Army
Ronan Thompson Foundation
The Catherine Elizabeth Blair Memorial Foundation
Cookies for Kids' Cancer
Information provided by (Responsible Party):
New Approaches to Neuroblastoma Therapy Consortium
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2024 |
| Estimated Study Completion Date : | December 2025 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):